GenoTech Corp
KKRX:0668301,199.00
KRW
-1.00
(-0.08%)
ISIN
KR7066830001
Return %
Stock
S&P 500
1Y
9.50
13.14
3Y
-36.99
80.78
5Y
-67.15
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Jong Kim
- Full Time Employees
- 34
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Daejeon South Korea
- IPO Date
- Jul 18, 2016
- Website
- genotech.co.kr
- Similar Companies
- Business
- GenoTech Corp. is a South Korea-based biotechnology and life sciences company that specializes in artificial gene synthesis, genome sequencing and analysis services, molecular diagnostics, and biopharmaceutical raw materials. Founded in July 1997 and headquartered in Daejeon, South Korea, the company operates across three principal business segments: Gene Synthesis, Genome Analysis, and Molecular Diagnostics and Biopharmaceuticals. In its Gene Synthesis division, the company manufactures and supplies custom oligonucleotide synthesis products, including standard single-stranded DNA oligonucleotides; chemically modified oligonucleotides featuring amino, thiol, and phosphorylation linkages; dual-labeled fluorescent probes such as TaqMan probes and Molecular Beacons for quantitative real-time PCR; custom RNA oligonucleotides; and gene synthesis constructs tailored for academic, medical, and industrial research applications. In its Genome Analysis division, GenoTech offers automated high-throughput Sanger DNA sequencing services, comprising standard sequencing, 16S and ITS ribosomal RNA microbial identification sequencing, insert clone sequencing, and primer walking; Next-Generation Sequencing (NGS) solutions, including whole genome sequencing, whole exome sequencing, targeted amplicon sequencing, and transcriptomics (RNA-Seq); and custom bioinformatics data interpretation services. In its Molecular Diagnostics and Biopharmaceuticals segment, the company develops and produces in vitro diagnostic (IVD) kits and reagents, encompassing genetic mutation detection kits; tuberculosis diagnostic assays; single nucleotide polymorphism (SNP) genotyping kits; agricultural, marine, and livestock breed verification kits; real-time PCR master mixes; and Active Pharmaceutical Ingredients (APIs) and biopharmaceutical materials, including Vancomycin HCl, Teicoplanin, and Tacrolimus. GenoTech serves universities, academic research institutes, biopharmaceutical enterprises, clinical laboratories, hospital diagnostic centers, and government research bodies primarily across South Korea and key regional markets in Asia. In recent operational developments, GenoTech has expanded its precision molecular diagnostics portfolio by executing national research and development initiatives focused on real-time PCR-based genetic screening and specialized biological resource authentication kits. The company has also participated in Korea Exchange (KRX) KONEX investor initiatives to highlight its scaled manufacturing capacity for high-value biopharmaceutical raw materials and automated genomic synthesis infrastructure, while strengthening its contract research partnerships to support growing clinical diagnostic and industrial biotechnology pipelines.